학술논문
Monitoring the outcomes of non‐pharmacological treatments for cognitive impairment using magnetoencephalography: A case series
Document Type
Clinical report
Author
Source
Clinical Case Reports. January 2024, Vol. 12 Issue 1
Subject
Language
English
Abstract
INTRODUCTION Dementia and mild cognitive impairment (MCI) are syndromes characterized by cognitive deterioration due to brain diseases, such as Alzheimer's disease. Although only few effective drugs are available to treat [...]
Key Clinical Message: Cognitive impairment associated dementia is treatable non‐pharmacologically. Monitoring tools are important to provide proper treatment. The present study showed that the resting‐state brain activity measured using magnetoencephalography reflects their outcomes and captures clinical impressions better than neuropsychological assessments, which have inherent limitations such as the practice effect. Abstract: Mild cognitive impairment (MCI) is a prodromal phase of dementia caused by brain diseases. Non‐pharmacological treatments are sometimes effective in improving patient's cognition and quality of life. To provide better treatments, monitoring the treatment outcomes, which is done using neuropsychological assessments, is important. However, these assessments have inherent limitations, such as practice effects. Therefore, complementary assessments are anticipated. Magnetoencephalography (MEG) is a neuroimaging technique that is sensitive to changes in brain activity associated with cognitive impairment. It represents the state of brain activity in terms of MEG spectral parameters associated with neuropsychological assessment scores. MEG spectral parameters could reasonably be used to monitor treatment outcomes without the aforementioned limitations. However, few published longitudinal reports have assessed MEG spectral parameters during the non‐pharmacological treatment period for cognitive impairment associated with dementia. In this study, we retrospectively examined the clinical records of two patients with MCI. Changes in neuropsychological assessment scores and MEG spectral parameters were qualitatively evaluated along with the patients' conditions, as described in the medical records during non‐pharmacological treatments provided for more than 2 years. The changes in neuropsychological assessment scores and MEG spectral parameters showed comparable trends, with some discrepancies. Changes in MEG spectral parameters were more consistent with the subjective reports from caregivers and medical staff in the medical records. Our results suggest that MEG is a promising tool for monitoring patient conditions during treatment.
Key Clinical Message: Cognitive impairment associated dementia is treatable non‐pharmacologically. Monitoring tools are important to provide proper treatment. The present study showed that the resting‐state brain activity measured using magnetoencephalography reflects their outcomes and captures clinical impressions better than neuropsychological assessments, which have inherent limitations such as the practice effect. Abstract: Mild cognitive impairment (MCI) is a prodromal phase of dementia caused by brain diseases. Non‐pharmacological treatments are sometimes effective in improving patient's cognition and quality of life. To provide better treatments, monitoring the treatment outcomes, which is done using neuropsychological assessments, is important. However, these assessments have inherent limitations, such as practice effects. Therefore, complementary assessments are anticipated. Magnetoencephalography (MEG) is a neuroimaging technique that is sensitive to changes in brain activity associated with cognitive impairment. It represents the state of brain activity in terms of MEG spectral parameters associated with neuropsychological assessment scores. MEG spectral parameters could reasonably be used to monitor treatment outcomes without the aforementioned limitations. However, few published longitudinal reports have assessed MEG spectral parameters during the non‐pharmacological treatment period for cognitive impairment associated with dementia. In this study, we retrospectively examined the clinical records of two patients with MCI. Changes in neuropsychological assessment scores and MEG spectral parameters were qualitatively evaluated along with the patients' conditions, as described in the medical records during non‐pharmacological treatments provided for more than 2 years. The changes in neuropsychological assessment scores and MEG spectral parameters showed comparable trends, with some discrepancies. Changes in MEG spectral parameters were more consistent with the subjective reports from caregivers and medical staff in the medical records. Our results suggest that MEG is a promising tool for monitoring patient conditions during treatment.